Osseous tissue engineering with gene therapy for facial bone reconstruction.
OBJECTIVE
Facial osseous defects remain a major functional and esthetic challenge for the head and neck surgeon. Tissue engineering may provide advantageous alternatives to conventional therapies. The objective of the study was to evaluate the efficacy of gene therapy in the repair of osseous facial defects.


METHODS
Blinded, controlled, prospective animal experiment.


METHODS
Thirty adult athymic nude rats were divided into five groups of six animals. Three groups were used as control subjects. Two groups were treated with 3.75 x 10(8) viral particles containing recombinant type 5 adenoviral vectors. One group received viruses that coded for beta-galactosidase production, another received viruses that coded for bone morphogenetic protein (BMP-2) production. After 120 days rats were examined at necropsy with precise planimetry, histological analysis of new bone growth, and radio-densitometric analysis of bone thickness.


RESULTS
Radio-densitometric measurements showed that BMP-2-treated nude athymic rats had significantly enhanced osseous repair compared with control subjects when evaluated by both radio-densitometry and histological examination.


CONCLUSIONS
Gene therapy-treated, immunosuppressed rodents had an enhanced osteoinductive repair of a dorsal osseous nasal defect.
Lindsey
W H
WH
Northern Virginia Center for Facial Plastic Surgery, Reston, Virginia 20191, USA.
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D019485:Bone Morphogenetic Proteins; D001861:Bone Regeneration / Q000502:physiology; D003720:Densitometry; D005147:Facial Bones / Q000601:surgery; D015316:Genetic Therapy; D005822:Genetic Vectors; D007165:Immunosuppression Therapy; D011446:Prospective Studies; D051381:Rats; D011923:Rats, Nude; D019651:Plastic Surgery Procedures; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D001616:beta-Galactosidase
D019485:Bone Morphogenetic Proteins; D001616:beta-Galactosidase